Vidarabine
Vira-a (vidarabine) is a small molecule pharmaceutical. Vidarabine was first approved as Vira-a on 1982-01-01. It is used to treat chickenpox, herpes simplex, herpes zoster, herpetic keratitis, and infectious keratoconjunctivitis in the USA. The pharmaceutical is active against adenosine deaminase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vidarabine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VIRA-A | Parkedale Pharmaceuticals | N-050486 DISCN | 1982-01-01 | 1 products |
| VIRA-A | Parkedale Pharmaceuticals | N-050523 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AB: Nucleosides and nucleotides excl. reverse transcriptase inhibitors
— J05AB03: Vidarabine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AD: Antivirals, ophthalmologic
— S01AD06: Vidarabine
HCPCS
No data
Clinical
Clinical Trials
5892 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis | D006505 | — | K75.9 | 131 | 221 | 125 | 95 | 194 | 719 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 163 | 146 | 97 | 58 | 163 | 603 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 105 | 190 | 101 | 86 | 154 | 595 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | 143 | 181 | 123 | 70 | 101 | 576 |
| Hepatitis c | D006526 | — | B19.2 | 99 | 178 | 128 | 65 | 139 | 572 |
| Infections | D007239 | EFO_0000544 | — | 125 | 159 | 87 | 22 | 172 | 524 |
| Covid-19 | D000086382 | — | U07.1 | 60 | 108 | 79 | 31 | 189 | 430 |
| Virus diseases | D014777 | — | B34 | 125 | 126 | 61 | 13 | 107 | 406 |
| Leukemia | D007938 | — | C95 | 143 | 190 | 63 | 4 | 16 | 356 |
| Hepatitis b | D006509 | — | — | 68 | 111 | 64 | 42 | 93 | 353 |
Show 209 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 64 | 94 | 30 | — | 11 | 177 |
| Myelodysplastic syndromes | D009190 | — | D46 | 64 | 101 | 10 | — | 9 | 154 |
| Recurrence | D012008 | — | — | 53 | 63 | 8 | — | 11 | 114 |
| Lymphoid leukemia | D007945 | — | C91 | 39 | 54 | 23 | — | 4 | 105 |
| Dengue | D003715 | — | A90 | 45 | 27 | 11 | — | 13 | 94 |
| Preleukemia | D011289 | — | — | 32 | 53 | 3 | — | 2 | 73 |
| Hodgkin disease | D006689 | — | C81 | 26 | 42 | 6 | — | 10 | 71 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 23 | 39 | 5 | — | 7 | 64 |
| Melanoma | D008545 | — | — | 38 | 28 | 3 | — | 3 | 62 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 16 | 42 | 4 | — | 5 | 62 |
Show 204 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 33 | 9 | — | — | 4 | 41 |
| T-cell lymphoma | D016399 | — | — | 12 | 23 | — | — | 4 | 33 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 15 | 18 | — | — | 2 | 31 |
| Burkitt lymphoma | D002051 | — | C83.7 | 11 | 20 | — | — | 4 | 30 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 13 | 23 | — | — | 2 | 29 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 10 | 18 | — | — | 5 | 29 |
| Zika virus infection | D000071243 | — | A92.5 | 15 | 2 | — | — | 12 | 29 |
| Prostatic neoplasms | D011471 | — | C61 | 13 | 17 | — | — | 2 | 27 |
| Lung neoplasms | D008175 | — | C34.90 | 19 | 7 | — | — | 3 | 25 |
| Adenoviridae infections | D000257 | EFO_1001259 | B34.0 | 20 | 10 | — | — | 4 | 25 |
Show 366 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis | D003872 | — | L30.9 | 1 | — | — | — | 6 | 7 |
| Varicella zoster virus infection | D000073618 | — | — | 2 | — | — | — | 5 | 7 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | — | — | — | 6 | 7 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 5 | — | — | — | 1 | 6 |
| Emergencies | D004630 | — | — | 2 | — | — | — | 4 | 6 |
| Suicide | D013405 | — | — | 2 | — | — | — | 3 | 5 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 4 | — | — | — | — | 4 |
| Medulloblastoma | D008527 | — | — | 4 | — | — | — | — | 4 |
| Hiv seronegativity | D018023 | — | — | 4 | — | — | — | — | 4 |
| Lassa fever | D007835 | EFO_0007338 | A96.2 | 3 | — | — | — | 1 | 4 |
Show 125 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 6 | 6 |
| Community-acquired pneumonia | D000098968 | — | — | — | — | — | — | 5 | 5 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 5 | 5 |
| Recreational drug use | D000084783 | — | — | — | — | — | — | 5 | 5 |
| Rhinovirus | D012229 | — | — | — | — | — | — | 5 | 5 |
| Critical illness | D016638 | — | — | — | — | — | — | 5 | 5 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | — | — | — | 4 | 4 |
| Neck pain | D019547 | — | M54.2 | — | — | — | — | 4 | 4 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | — | — | 4 | 4 |
| Gonorrhea | D006069 | DOID_7551 | A54 | — | — | — | — | 4 | 4 |
Show 399 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vidarabine |
| INN | vidarabine |
| Description | Adenine arabinoside is a purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. It has a role as an antineoplastic agent, a bacterial metabolite and a nucleoside antibiotic. It is a purine nucleoside and a beta-D-arabinoside. It is functionally related to an adenine. |
| Classification | Small molecule |
| Drug class | antineoplastics (arabinofuranosyl derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 5536-17-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1090 |
| ChEBI ID | 45327 |
| PubChem CID | 21704 |
| DrugBank | DB00194 |
| UNII ID | 3XQD2MEW34 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Vidarabine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,366 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,536 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use